Researchers have already developed models of many of the major organs (see diagram). Lars Küpfer at Bayer Technology Services, a pharmaceutical company in Leverkusen, Germany, and colleagues have created a virtual liver, for example, which they can use to investigate the toxicity of substances such as paracetamol. "The virtual human is the ultimate goal of computational biology," says Küpfer. "Current models, including the ones we are using, are important milestones along the way."
The ability to simulate biological functions is becoming important for developing more effective drugs. "Pharma companies are in trouble using their existing routes," says Coveney. Drugs often don't work for significant subsets of the population. "It's not one size fits all."
One of the goals of the Virtual Physiological Human project is for people to participate in their own medical care, simulating the outcomes of certain choices and even self-diagnosing. But with control comes responsibility. Will we listen to our simulated self?
New Scientist (sub required)
Click on image to enlarge
Adobe + EchoSign = end of fax and Fedex and printer ink?
Are we truly nearing - finally - a paperless state?
From Adobe's announcement of EchoSign (the electronic signature company) acquisition
"EchoSign's solution, which currently supports more than three million users worldwide, will be offered as part of Adobe's online document exchange services platform. The EchoSign solution will be integrated with other Adobe(R) document services including SendNow for managed file transfer, FormsCentral for form creation and CreatePDF for online PDF creation. By reducing the time and costs of having documents signed with traditional methods, such as fax and overnight envelopes, the EchoSign solution can enable customers to significantly accelerate sales cycles, improve tracking and centralize the management of signed agreements through a simple to use cloud service."
Photo Credit
August 11, 2011 in Digital Imaging, Imaging, Industry Commentary | Permalink | Comments (1) | TrackBack (0)